Fortunes diverge for solo drug launchers

Fortunes diverge for solo drug launchers

Source: 
EP Vantage
snippet: 

he first-quarter reporting season is in full swing, and in the spotlight are several drug launches being undertaken by small developers. The pandemic is making life tough for biopharma groups big and small, but for some Covid-19 is arguably providing a smokescreen for a poor performance or product.

This analysis by Evaluate Vantage shows that not all small company launches go disastrously – witness Biocryst’s impressive first quarter. Elsewhere, the jury is still out on the likes of Global Blood and Morphosys, but things look grim for Esperion.